Article

Functional testing of PI3K inhibitors stratifies responders to idelalisib and identifies treatment vulnerabilities in idelalisib-refractory/intolerant chronic lymphocytic leukemia

2022-04-15

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Purpose</h4> Phosphatidylinositol 3-kinase inhibitors (PI3Ki) are approved for relapsed chronic lymphocytic leukemia (CLL). While patients may show an initial response, development of treatment intolerance or resistance remains a clinically challenging. Prediction of individual treatment responses based on clinically actionable biomarkers is needed to overcome these challenges. Here, we inv...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 01e09ac9-c772-569a-83d9-98846b5f6de3
DOI: 10.1101/2022.04.14.488428

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Functional testing of PI3K inhibitors stratifies responders to idelalisib and identifies treatment vulnerabilities in idelalisib-refractory/intolerant chronic lymphocytic leukemiaDOI 10.1101/2022.04.14.488428Read

Idelalisib — A PI3Kδ Inhibitor for B-Cell CancersSemantic proximity Read

Emerging Therapies in CLL in the Era of Precision MedicineSemantic proximity Read

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.Semantic proximity Read

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.Semantic proximity Read

Drug-perturbation-based stratification of blood cancerSemantic proximity Read

The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell FunctionSemantic proximity Read

How should we sequence and combine novel therapies in CLL?Semantic proximity Read

Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.Semantic proximity Read

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.Semantic proximity Read

Patterns of resistance to B cell-receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management.Semantic proximity Read

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapiesSemantic proximity Read

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.Semantic proximity Read